Chemistry:Flunitazene
From HandWiki
Short description: Designer drug with opioid effects
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C20H23FN4O2 |
| Molar mass | 370.428 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Flunitazene (Fluonitazene) is a benzimidazole derivative with opioid effects, first developed in the 1950s as part of the research that led to better-known compounds such as etonitazene. It is one of the least potent derivatives from this class to have appeared as a designer drug, with only around the same potency as morphine, but nevertheless has been sold since around 2020, and has been linked to numerous drug overdose cases.[1][2][3][4][5][6]
See also
References
- ↑ ""Etazene, safer than heroin and fentanyl": Non-fentanyl novel synthetic opioid listings on one darknet market". Drug and Alcohol Dependence 225: 108790. August 2021. doi:10.1016/j.drugalcdep.2021.108790. PMID 34091156.
- ↑ "A review of the evidence on the use and harms of 2-benzyl benzimidazole ('nitazene') and piperidine benzimidazolone ('brorphine-like') opioids.". UK: Advisory Council on the Misuse of Drugs. July 2022. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1091152/ACMD_advice_on_2-benzyl_benzimidazole_and_piperidine_benzimidazolone_opioids.pdf.
- ↑ "A Forward-Thinking Approach to Addressing the New Synthetic Opioid 2-Benzylbenzimidazole Nitazene Analogs by Liquid Chromatography-Tandem Quadrupole Mass Spectrometry (LC-QQQ-MS)". Journal of Analytical Toxicology 46 (3): 221–231. March 2022. doi:10.1093/jat/bkab117. PMID 34792157.
- ↑ "Acute Intoxications and Fatalities Associated With Benzimidazole Opioid (Nitazene Analog) Use: A Systematic Review". Therapeutic Drug Monitoring 44 (4): 494–510. August 2022. doi:10.1097/FTD.0000000000000970. PMID 35149665.
- ↑ "High-throughput quantification of emerging nitazene benzimidazole opioid analogs by microextraction and UHPLC-MS/MS". Journal of Analytical Toxicology 47 (9): 787–796. September 2023. doi:10.1093/jat/bkad071. PMID 37700512.
- ↑ "Challenges in Drug Surveillance: Strengthening the Analysis of New Psychoactive Substances by Harmonizing Drug Checking Services in Proficiency Testing". International Journal of Environmental Research and Public Health 20 (5): 4628. March 2023. doi:10.3390/ijerph20054628. PMID 36901637.
 |  |
